Osteoarthritis, Knee
Conditions
Keywords
Osteoarthritis, knee pain, osteoarthritic knee pain
Brief summary
To investigate the safety, efficacy and pharmacokinetics of single daily oral dose of LY2828360 in male and female subjects with osteoarthritic knee pain
Interventions
DRUGLY2828360
Administered orally
DRUGPlacebo
Administered orally
Sponsors
Eli Lilly and Company
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
40 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Are male or female participants with osteoarthritis (OA), as determined by medical history and physical examination. Males and females with stable medical problems that, in the investigator's opinion, will not significantly alter the disposition of the drug, will not place the participant at increased risk by participating in the study, and will not interfere with interpretation of the data. 1. Male participants: agree to use a reliable method of birth control during the study and for 3 months following the last dose of the investigational product 2. Female participants: women not of child-bearing potential due to surgical sterilization (at least 6 weeks post surgical bilateral oophorectomy with or without hysterectomy or tubal ligation) confirmed by medical history, or menopause * Body weight greater than 40 kilograms (kg) and less than 120 kilograms (kg) with a body mass index (BMI) between 19-35 kilograms per square meter (kg/m\^2) inclusive * Participant with osteoarthritic knee based on disease diagnostic criteria as presented in the Inclusion Disease Criteria, below * Blood pressure and pulse rate in supine and standing positions, within normal reference ranges for the population and investigator clinical research unit (CRU), or results with acceptable deviations that are judged to be not clinically significant by the investigator * Have clinical laboratory test results within normal reference range for the population or investigator clinical research unit (CRU), or results with acceptable deviations that are judged to be not clinically significant by the investigator * Have venous access sufficient to allow for blood sampling * Have agreed to maintain the same activity level throughout the course of the study Inclusion Disease Criteria: * Have a unilateral or bilateral osteoarthritis (OA) of the knee diagnosed according to the American College of Rheumatology (ACR) criteria. The clinical diagnosis of osteoarthritis (OA) will be confirmed by the American College of Rheumatology (ACR) clinical and radiographic criteria for classification of idiopathic osteoarthritis (OA) of the knee based upon the following criteria: 1. Knee pain for at least 14 days per month for the 3 months before screening 2. Osteophytes (with radiographic evidence) 3. At least 1 of the following 3 conditions: Age greater than 50, or Morning stiffness less than 30 minutes, or Crepitus * Have a Kellgren and Lawrence grade of I, II, III or IV * Have a mean score of at least 4 (moderate) and less than or equal to 8 (moderate-severe) on the 24-hour average pain score (0-10) (question 1) in the participant e-diary from screening to randomization for the knee joint during walking * Discontinued use of all analgesic medications (including over-the-counter \[OTC\] analgesics/Non-Steroidal Anti-Inflammatory Drug \[NSAID\]) at least 2 weeks prior to randomization (participants are allowed limited use of analgesic medications)
Exclusion criteria
* Are currently enrolled in, have completed or discontinued within the last 3 months from, a clinical trial involving an off-label investigational drug or device or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study * Have known allergies to LY2828360, related compounds or any components of the formulation * Have an abnormality in the 12-lead electrocardiogram (ECG) at screening that, in the opinion of the investigator, increases the risks associated with participation in the study * Have a recent or current history of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data * Have current or previous (within the past year) Axis 1 diagnosis of major depressive disorder, mania, bipolar disorder, psychosis, dysthymia, generalized anxiety disorder, alcohol or eating disorders according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision, criteria, as determined by the investigator and confirmed by the Mini-International Neuropsychiatric Interview * Are judged by the Principal Investigator to be clinically at suicidal risk based upon clinical interview * Have intercurrent illness or clinically significant adverse events * Have increased risk of seizures as evidenced by a history of seizures, stroke, surgery to the cerebral cortex, or head trauma with loss of consciousness * Have an alanine aminotransaminase (ALT) greater than 2.5 times Upper Limit of Normal (ULN) at Screening, based on reference ranges of the local laboratory. Moderate or greater hepatic impairment * Have prior renal transplant, current renal dialysis or severe renal insufficiency, or serum creatinine laboratory value greater than 1.5 times Upper Limit of Normal, based on the reference ranges of the local laboratory * Have clinically significant abnormal neurological examination, especially any evidence of tremor or nystagmus * Have a history of or symptoms suggestive of sleep apnoea * Use of any known strong inducers or inhibitors of Cytochrome P450 within 30 days prior to enrolment. * Regularly use known drugs of abuse and/or show positive findings on urinary drug screening * Have a positive alcohol breath test at Screening * Show evidence of human immunodeficiency virus infection and/or positive human HIV antibodies * Have an active malignancy of any type or a history of malignancy (except basal cell carcinoma of the skin that has been excised prior to study start) * Are at a high risk of infection * Have an autoimmune disorder * Show evidence of hepatitis C and/or positive hepatitis C antibody * Show evidence of hepatitis B and/or positive hepatitis B surface antigen * Are women with a positive pregnancy test or women who are lactating or child bearing * Use prescription and herbal medications that cannot safely be discontinued by end of screening * Have donated blood of more than 500 milliliters (mL) within the last 3 months * Have an average weekly alcohol intake that exceeds 21 units per week (males up to age 65) and 14 units per week (males over 65 and females), or are unwilling to refrain alcohol consumption for the duration of the study * Are persons who have previously received the investigational product in study, have completed or withdrawn from this study or any other study investigation LY2828360 * Are taking any excluded medications (analgesic medications) and over-the- counter medications that cannot be discontinued at screening * Show evidence or have any prior history of significant active neurological or psychiatric disease including depression Exclusion Disease Criteria: * Have secondary causes of arthritis of the knee including septic arthritis, inflammatory joint disease, articular fracture, major dysplasias or congenital abnormality, ochronosis, acromegaly, hemochromatosis, Wilson's disease, and primary osteochondromatosis * Have had lower extremity surgery (including arthroscopy of the index knee) within 6 months prior to Screening or have surgery planned of the index knee at anytime * Have had significant prior injury to the index knee within 12 months prior to Screening * Use of lower extremity assistive devices other than a cane or knee brace (use of a 'shoe lift' is permitted). Are non-ambulatory or require the use of crutches or a walker. Use of a cane in the hand opposite the index knee is acceptable * Have a confounding painful condition that may interfere with assessment of the index joint, that is, knee * Have any other musculoskeletal or arthritic condition that may affect the interpretation of clinical efficacy and/or safety data or otherwise contraindicates participation in this clinical study * Have used corticosteroid prior to baseline * Have received hyaluronan injections into index knee within the previous 6 months prior to Treatment Phase day 3 * Have initiated or have changed to an established physiotherapy program within 2 weeks prior to Treatment Phase day 3 or during the study period An established physiotherapy program may be continued throughout the study period if unchanged in frequency and intensity * Has had a prior synovial fluid analysis showing a White Blood Cell (WBC) greater than or equal to 2000 cubic millimeters (mm\^3) that is indicative of a diagnosis other than OA * Have started recently or changed dose regimen of any OA specific therapies (that is, nutraceutical products)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline to 4 Week Endpoint in Weekly Mean of Daily 24-Hour Average Pain Scores (APS) | Baseline, 4 weeks | The weekly mean of the 24-Hour APS was calculated from participants' daily entries for 24-hour average pain rating on an 11-point scale with scores from 0 (no pain) to 10 (worst possible pain). Data were recorded twice a day at approximately the same time each day, preferably first thing in the morning and in the afternoon. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetics (PK) of LY2828360: Area Under the Concentration-Time Curve (AUC) | Pre-last dose to 8 hours post-last dose (at end of each 4-week treatment period) | AUC from time zero to 8 hours (AUC0-8h) is reported for this outcome measure. |
| Change From Baseline to 4 Week Endpoint in Weekly Mean of Night Pain and Worst Daily Pain Scores | Baseline, 4 weeks | The pain severity for night pain and worst pain was measured by an 11-point Likert scale, an ordinal scale with scores from 0 (no pain) to 10 (worst possible pain). The 11-point Likert scale was used for assessment of night pain and worst pain each day, and evaluated as weekly means. Participants were asked to complete the severity pain for worst pain twice a day (in the morning and in the afternoon). The pain severity for night pain was filled out only once in the morning. |
| Change From Baseline to 4 Week Endpoint in Chronic Pain Sleep Inventory (CPSI) | Baseline, 4 weeks | The CPSI is a validated 5-item questionnaire in which the following factors were assessed: trouble falling asleep due to pain (CPSI1), the need for sleep medication (CPSI2), awakenings by pain during the night (CPSI3) awakenings by pain in the morning (CPSI4), and overall sleep quality (CSPI5). All CPSI items are scored using a 100-millimeter (mm) visual analog scale (VAS) (VAS; 0=never and 100=always for CPSI1 through CPSI4, and 0=very poor and 100=excellent for CPSI5). |
| Change From Baseline to 4 Week Endpoint in Pittsburgh Sleep Quality Index (PSQI) | Baseline, 4 weeks | The PSQI is a self-rated questionnaire that assesses the participant's sleep habits during the last month and consists of 19 questions that cover 7 components (sleep quality, sleep onset latency, sleep duration, sleep efficiency, sleep disturbances, sleeping medication use, and daytime dysfunction). Each item has a range of 0 (no difficulty) to 3 (severe difficulty). The 7 component scores were added to yield a global score with a range of 0 (no difficulty) to 21 (severe difficulties in all areas). |
| Change From Baseline to 4 Week Endpoint in Brief Pain Inventory Severity and Interference Scores (BPI-S/BPI-I) | Baseline, 4 weeks | The BPI-S and BPI-I are self-reported scales measuring severity of pain and interference on function. BPI-S consists of 4 questions assessing worst pain, least pain, average pain in the past 24 hours, and pain right now. Severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine). The BPI-I average interference is the average of 7 questions assessing interference of pain for general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. Average interference scores range: 0 (does not interfere) to 10 (completely interferes). |
| Change From Baseline to 4 Week Endpoint in Investigator Global Assessment of Changes (IGAC) | Baseline, 4 weeks | The IGAC is an investigator-reported subjective evaluation using a 100 millimeter (mm) visual analog scale (VAS) to answer the following question: If you take into consideration all the various ways the knee pain influence the participant and his/her life, how do you then evaluate the participant's condition today (0=very good and 100=very bad). |
| Pharmacokinetics (PK) of LY2828360: Maximal Concentration (Cmax) | Pre-last dose to 8 hours post-last dose (at end of each 4-week treatment period) | — |
| Change From Baseline to 4 Week Endpoint in Western Ontario and MacMaster (WOMAC) | Baseline, 4 weeks | WOMAC index completed by participant; consists of 24 questions, each based on 5-point Likert scale (0=none to 4=extreme). Has 3 subscales: pain, stiffness, and physical function. Pain subscale has 5 questions on pain associated with everyday tasks; subscale score ranges from 0=none to 20=extreme. Physical function subscale has 17 questions on physical function difficulties with everyday tasks; subscale score ranges from 0=none to 68=extreme. Stiffness subscale has 2 questions on stiffness associated with time of day (morning versus later in day); subscale score ranges from 0=none to 8=extreme. |
| Change From Baseline to 4 Week Endpoint in Pain From 40 Meter Self-Paced Walk Test | Baseline, 4 weeks | The 40 meter self-paced walk test is a participant-rated subjective evaluation using a 100 millimeter (mm) visual analog scale (VAS) to assess pain after walking 40 meters. Scores range from 0 (no pain) to 100 (worst pain). |
| Change From Baseline to 4 Week Endpoint in the 11 Step Stair Climb Test | Baseline, 4 weeks | The 11 step stair climb test is a participant-rated subjective evaluation using a 100 millimeter (mm) visual analog scale (VAS) to assess pain after climbing 11 stairs. Scores range from 0 (no pain) to 100 (worst pain). |
| Change From Baseline to 4 Week Endpoint in DoloTest Sum Score | Baseline, 4 weeks | The DoloTest® is a self-reported assessment composed of 8 visual analog scale (VAS) items ranging from 0 (none) to 100 (worst possible) for the following domains: pain, problems with light physical activities, problems with more strenuous physical activities, problems doing your job, reduced energy and strength, low spirit, reduced social life, and problems sleeping). The scale is arranged in a radar plot to provide a graphic presentation of the test result. The DoloTest® Sum Score is equal to the sum of each scored domain; scores range from 0 (none) to 800 (worst possible). |
| Number of Participants With Treatment-Emergent Suicidal Ideation and Behaviors Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) | Baseline up to 15 weeks | C-SSRS: scale capturing occurrence, severity, and frequency of suicide-related thoughts and behaviors. Number of participants with suicidal behaviors and ideations are provided. Suicidal behavior: a yes answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal ideation: a yes answer to any one of 5 suicidal ideation questions, which includes wish to be dead, and 4 different categories of active suicidal ideation. |
| Change From Baseline to 4 Week Endpoint in Patient Global Assessment of Changes (PGAC) | Baseline, 4 weeks | The PGAC is a self-reported subjective evaluation using a 100 millimeter (mm) visual analog scale (VAS) to answer the following question: If you take into consideration all the various ways the knee pain influence you and your life how do you then evaluate your condition over the last week (0=very good and 100=very bad). |
Countries
Denmark
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| 80 mg LY2828360 First, Then Placebo Participants received 80 milligrams (mg) of LY2828360 once daily by mouth for 4 weeks, followed by a 3-week washout period, then placebo once daily by mouth for 4 weeks. | 20 |
| Placebo First, Then 80 mg LY2828360 Participants received placebo once daily by mouth for 4 weeks, followed by a 3-week washout period, then 80 mg of LY2828360 once daily by mouth for 4 weeks. | 19 |
| Total | 39 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| First Treatment Period (4 Weeks) | Adverse Event | 2 | 0 |
| First Treatment Period (4 Weeks) | Protocol Violation | 0 | 1 |
| First Treatment Period (4 Weeks) | Withdrawal by Subject | 1 | 1 |
| Second Treatment Period (4 Weeks) | Adverse Event | 1 | 0 |
| Second Treatment Period (4 Weeks) | Sponsor Decision | 0 | 1 |
Baseline characteristics
| Characteristic | 80 mg LY2828360 First, Then Placebo | Total | Placebo First, Then 80 mg LY2828360 |
|---|---|---|---|
| Age, Continuous | 64.7 years STANDARD_DEVIATION 6.6 | 63.3 years STANDARD_DEVIATION 6.9 | 61.9 years STANDARD_DEVIATION 7.1 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 20 Participants | 39 Participants | 19 Participants |
| Region of Enrollment Denmark | 20 Participants | 39 Participants | 19 Participants |
| Sex: Female, Male Female | 5 Participants | 14 Participants | 9 Participants |
| Sex: Female, Male Male | 15 Participants | 25 Participants | 10 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 14 / 37 | 16 / 36 |
| serious Total, serious adverse events | 0 / 37 | 0 / 36 |
Outcome results
Primary
Change From Baseline to 4 Week Endpoint in Weekly Mean of Daily 24-Hour Average Pain Scores (APS)
The weekly mean of the 24-Hour APS was calculated from participants' daily entries for 24-hour average pain rating on an 11-point scale with scores from 0 (no pain) to 10 (worst possible pain). Data were recorded twice a day at approximately the same time each day, preferably first thing in the morning and in the afternoon.
Time frame: Baseline, 4 weeks
Population: The analysis included all randomized participants receiving at least 1 dose of the investigational product and with a baseline and at least 1 post-baseline weekly mean 24-Hour Average Pain value.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| 80 mg LY2828360 | Change From Baseline to 4 Week Endpoint in Weekly Mean of Daily 24-Hour Average Pain Scores (APS) | -0.90 units on a scale | Standard Deviation 1.03 |
| Placebo | Change From Baseline to 4 Week Endpoint in Weekly Mean of Daily 24-Hour Average Pain Scores (APS) | -1.20 units on a scale | Standard Deviation 1.5 |
Secondary
Change From Baseline to 4 Week Endpoint in Brief Pain Inventory Severity and Interference Scores (BPI-S/BPI-I)
The BPI-S and BPI-I are self-reported scales measuring severity of pain and interference on function. BPI-S consists of 4 questions assessing worst pain, least pain, average pain in the past 24 hours, and pain right now. Severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine). The BPI-I average interference is the average of 7 questions assessing interference of pain for general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. Average interference scores range: 0 (does not interfere) to 10 (completely interferes).
Time frame: Baseline, 4 weeks
Population: The analysis included all randomized participants receiving at least 1 dose of the investigational product and with baseline and at least 1 postbaseline BPI-S/BPI-I value.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| 80 mg LY2828360 | Change From Baseline to 4 Week Endpoint in Brief Pain Inventory Severity and Interference Scores (BPI-S/BPI-I) | BPI-S Least Pain | -0.6 units on a scale | Standard Deviation 1 |
| 80 mg LY2828360 | Change From Baseline to 4 Week Endpoint in Brief Pain Inventory Severity and Interference Scores (BPI-S/BPI-I) | BPI-S Pain Right Now | -0.6 units on a scale | Standard Deviation 1.4 |
| 80 mg LY2828360 | Change From Baseline to 4 Week Endpoint in Brief Pain Inventory Severity and Interference Scores (BPI-S/BPI-I) | BPI-S Average Pain in the Past 24 Hours | -0.9 units on a scale | Standard Deviation 1.1 |
| 80 mg LY2828360 | Change From Baseline to 4 Week Endpoint in Brief Pain Inventory Severity and Interference Scores (BPI-S/BPI-I) | BPI-I Average Interference | -0.7 units on a scale | Standard Deviation 1.2 |
| 80 mg LY2828360 | Change From Baseline to 4 Week Endpoint in Brief Pain Inventory Severity and Interference Scores (BPI-S/BPI-I) | BPI-S Worst Pain | -1.0 units on a scale | Standard Deviation 1.7 |
| Placebo | Change From Baseline to 4 Week Endpoint in Brief Pain Inventory Severity and Interference Scores (BPI-S/BPI-I) | BPI-I Average Interference | -0.8 units on a scale | Standard Deviation 1.2 |
| Placebo | Change From Baseline to 4 Week Endpoint in Brief Pain Inventory Severity and Interference Scores (BPI-S/BPI-I) | BPI-S Worst Pain | -1.0 units on a scale | Standard Deviation 1.9 |
| Placebo | Change From Baseline to 4 Week Endpoint in Brief Pain Inventory Severity and Interference Scores (BPI-S/BPI-I) | BPI-S Least Pain | -0.8 units on a scale | Standard Deviation 1.8 |
| Placebo | Change From Baseline to 4 Week Endpoint in Brief Pain Inventory Severity and Interference Scores (BPI-S/BPI-I) | BPI-S Average Pain in the Past 24 Hours | -1.1 units on a scale | Standard Deviation 1.6 |
| Placebo | Change From Baseline to 4 Week Endpoint in Brief Pain Inventory Severity and Interference Scores (BPI-S/BPI-I) | BPI-S Pain Right Now | -0.8 units on a scale | Standard Deviation 1.7 |
Secondary
Change From Baseline to 4 Week Endpoint in Chronic Pain Sleep Inventory (CPSI)
The CPSI is a validated 5-item questionnaire in which the following factors were assessed: trouble falling asleep due to pain (CPSI1), the need for sleep medication (CPSI2), awakenings by pain during the night (CPSI3) awakenings by pain in the morning (CPSI4), and overall sleep quality (CSPI5). All CPSI items are scored using a 100-millimeter (mm) visual analog scale (VAS) (VAS; 0=never and 100=always for CPSI1 through CPSI4, and 0=very poor and 100=excellent for CPSI5).
Time frame: Baseline, 4 weeks
Population: The analysis included all randomized participants receiving at least 1 dose of the investigational product and with a baseline and at least 1 postbaseline CPSI value.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| 80 mg LY2828360 | Change From Baseline to 4 Week Endpoint in Chronic Pain Sleep Inventory (CPSI) | CPSI2: Need for sleep medication | 0.0 units on a scale | Standard Deviation 0.3 |
| 80 mg LY2828360 | Change From Baseline to 4 Week Endpoint in Chronic Pain Sleep Inventory (CPSI) | CPSI4: Awakenings by pain in the morning | -0.4 units on a scale | Standard Deviation 1.1 |
| 80 mg LY2828360 | Change From Baseline to 4 Week Endpoint in Chronic Pain Sleep Inventory (CPSI) | CPSI3: Awakenings by pain during the night | -0.5 units on a scale | Standard Deviation 1.2 |
| 80 mg LY2828360 | Change From Baseline to 4 Week Endpoint in Chronic Pain Sleep Inventory (CPSI) | CPSI5: Overall sleep quality | 0.8 units on a scale | Standard Deviation 1.4 |
| 80 mg LY2828360 | Change From Baseline to 4 Week Endpoint in Chronic Pain Sleep Inventory (CPSI) | CPSI1: Trouble falling asleep due to pain | -0.6 units on a scale | Standard Deviation 0.9 |
| Placebo | Change From Baseline to 4 Week Endpoint in Chronic Pain Sleep Inventory (CPSI) | CPSI5: Overall sleep quality | 1.3 units on a scale | Standard Deviation 1.4 |
| Placebo | Change From Baseline to 4 Week Endpoint in Chronic Pain Sleep Inventory (CPSI) | CPSI1: Trouble falling asleep due to pain | -0.6 units on a scale | Standard Deviation 1.2 |
| Placebo | Change From Baseline to 4 Week Endpoint in Chronic Pain Sleep Inventory (CPSI) | CPSI2: Need for sleep medication | -0.1 units on a scale | Standard Deviation 0.5 |
| Placebo | Change From Baseline to 4 Week Endpoint in Chronic Pain Sleep Inventory (CPSI) | CPSI3: Awakenings by pain during the night | -0.8 units on a scale | Standard Deviation 1.5 |
| Placebo | Change From Baseline to 4 Week Endpoint in Chronic Pain Sleep Inventory (CPSI) | CPSI4: Awakenings by pain in the morning | -0.7 units on a scale | Standard Deviation 1.2 |
Secondary
Change From Baseline to 4 Week Endpoint in DoloTest Sum Score
The DoloTest® is a self-reported assessment composed of 8 visual analog scale (VAS) items ranging from 0 (none) to 100 (worst possible) for the following domains: pain, problems with light physical activities, problems with more strenuous physical activities, problems doing your job, reduced energy and strength, low spirit, reduced social life, and problems sleeping). The scale is arranged in a radar plot to provide a graphic presentation of the test result. The DoloTest® Sum Score is equal to the sum of each scored domain; scores range from 0 (none) to 800 (worst possible).
Time frame: Baseline, 4 weeks
Population: The analysis included all randomized participants receiving at least 1 dose of investigational product and with a baseline and at least 1 postbaseline DoloTest value.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| 80 mg LY2828360 | Change From Baseline to 4 Week Endpoint in DoloTest Sum Score | -34.5 units on a scale | Standard Deviation 90 |
| Placebo | Change From Baseline to 4 Week Endpoint in DoloTest Sum Score | -51.5 units on a scale | Standard Deviation 88.6 |
Secondary
Change From Baseline to 4 Week Endpoint in Investigator Global Assessment of Changes (IGAC)
The IGAC is an investigator-reported subjective evaluation using a 100 millimeter (mm) visual analog scale (VAS) to answer the following question: If you take into consideration all the various ways the knee pain influence the participant and his/her life, how do you then evaluate the participant's condition today (0=very good and 100=very bad).
Time frame: Baseline, 4 weeks
Population: The analysis included all randomized participants receiving at least 1 dose of the investigational product and with baseline and at least 1 postbaseline IGAC value.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| 80 mg LY2828360 | Change From Baseline to 4 Week Endpoint in Investigator Global Assessment of Changes (IGAC) | -8.6 units on a scale | Standard Deviation 15.6 |
| Placebo | Change From Baseline to 4 Week Endpoint in Investigator Global Assessment of Changes (IGAC) | -8.6 units on a scale | Standard Deviation 16.2 |
Secondary
Change From Baseline to 4 Week Endpoint in Pain From 40 Meter Self-Paced Walk Test
The 40 meter self-paced walk test is a participant-rated subjective evaluation using a 100 millimeter (mm) visual analog scale (VAS) to assess pain after walking 40 meters. Scores range from 0 (no pain) to 100 (worst pain).
Time frame: Baseline, 4 weeks
Population: The analysis included all randomized participants receiving at least 1 dose of the investigational product and with a baseline and at least 1 postbaseline 40 Meter Self-Paced Walk test value.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| 80 mg LY2828360 | Change From Baseline to 4 Week Endpoint in Pain From 40 Meter Self-Paced Walk Test | -7.8 units on a scale | Standard Deviation 18 |
| Placebo | Change From Baseline to 4 Week Endpoint in Pain From 40 Meter Self-Paced Walk Test | -8.4 units on a scale | Standard Deviation 24.7 |
Secondary
Change From Baseline to 4 Week Endpoint in Patient Global Assessment of Changes (PGAC)
The PGAC is a self-reported subjective evaluation using a 100 millimeter (mm) visual analog scale (VAS) to answer the following question: If you take into consideration all the various ways the knee pain influence you and your life how do you then evaluate your condition over the last week (0=very good and 100=very bad).
Time frame: Baseline, 4 weeks
Population: The analysis included all randomized participants who received at least 1 dose of the investigational product and with a baseline and at least 1 postbaseline PGAC value.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| 80 mg LY2828360 | Change From Baseline to 4 Week Endpoint in Patient Global Assessment of Changes (PGAC) | -9.6 units on a scale | Standard Deviation 21.7 |
| Placebo | Change From Baseline to 4 Week Endpoint in Patient Global Assessment of Changes (PGAC) | -10.5 units on a scale | Standard Deviation 21.3 |
Secondary
Change From Baseline to 4 Week Endpoint in Pittsburgh Sleep Quality Index (PSQI)
The PSQI is a self-rated questionnaire that assesses the participant's sleep habits during the last month and consists of 19 questions that cover 7 components (sleep quality, sleep onset latency, sleep duration, sleep efficiency, sleep disturbances, sleeping medication use, and daytime dysfunction). Each item has a range of 0 (no difficulty) to 3 (severe difficulty). The 7 component scores were added to yield a global score with a range of 0 (no difficulty) to 21 (severe difficulties in all areas).
Time frame: Baseline, 4 weeks
Population: The analysis included all randomized participants receiving at least 1 dose of the investigational product and with a baseline and at least 1 postbaseline PSQI value.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| 80 mg LY2828360 | Change From Baseline to 4 Week Endpoint in Pittsburgh Sleep Quality Index (PSQI) | -0.9 units on a scale | Standard Deviation 2.8 |
| Placebo | Change From Baseline to 4 Week Endpoint in Pittsburgh Sleep Quality Index (PSQI) | -0.7 units on a scale | Standard Deviation 1.5 |
Secondary
Change From Baseline to 4 Week Endpoint in the 11 Step Stair Climb Test
The 11 step stair climb test is a participant-rated subjective evaluation using a 100 millimeter (mm) visual analog scale (VAS) to assess pain after climbing 11 stairs. Scores range from 0 (no pain) to 100 (worst pain).
Time frame: Baseline, 4 weeks
Population: The analysis included all randomized participants receiving at least 1 dose of investigational product and with baseline and at least 1 postbaseline 11 Step Stair Climb Test value.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| 80 mg LY2828360 | Change From Baseline to 4 Week Endpoint in the 11 Step Stair Climb Test | -4.0 units on a scale | Standard Deviation 16 |
| Placebo | Change From Baseline to 4 Week Endpoint in the 11 Step Stair Climb Test | -9.0 units on a scale | Standard Deviation 23.9 |
Secondary
Change From Baseline to 4 Week Endpoint in Weekly Mean of Night Pain and Worst Daily Pain Scores
The pain severity for night pain and worst pain was measured by an 11-point Likert scale, an ordinal scale with scores from 0 (no pain) to 10 (worst possible pain). The 11-point Likert scale was used for assessment of night pain and worst pain each day, and evaluated as weekly means. Participants were asked to complete the severity pain for worst pain twice a day (in the morning and in the afternoon). The pain severity for night pain was filled out only once in the morning.
Time frame: Baseline, 4 weeks
Population: The analysis included all randomized participants receiving at least 1 dose of the investigational product and with a baseline night/worst pain value and at least 1 post-baseline weekly mean night/worst pain value.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| 80 mg LY2828360 | Change From Baseline to 4 Week Endpoint in Weekly Mean of Night Pain and Worst Daily Pain Scores | Night Pain | -0.80 units on a scale | Standard Deviation 1.08 |
| 80 mg LY2828360 | Change From Baseline to 4 Week Endpoint in Weekly Mean of Night Pain and Worst Daily Pain Scores | Worst Daily Pain | -0.85 units on a scale | Standard Deviation 1.27 |
| Placebo | Change From Baseline to 4 Week Endpoint in Weekly Mean of Night Pain and Worst Daily Pain Scores | Night Pain | -1.15 units on a scale | Standard Deviation 1.47 |
| Placebo | Change From Baseline to 4 Week Endpoint in Weekly Mean of Night Pain and Worst Daily Pain Scores | Worst Daily Pain | -1.25 units on a scale | Standard Deviation 1.62 |
Secondary
Change From Baseline to 4 Week Endpoint in Western Ontario and MacMaster (WOMAC)
WOMAC index completed by participant; consists of 24 questions, each based on 5-point Likert scale (0=none to 4=extreme). Has 3 subscales: pain, stiffness, and physical function. Pain subscale has 5 questions on pain associated with everyday tasks; subscale score ranges from 0=none to 20=extreme. Physical function subscale has 17 questions on physical function difficulties with everyday tasks; subscale score ranges from 0=none to 68=extreme. Stiffness subscale has 2 questions on stiffness associated with time of day (morning versus later in day); subscale score ranges from 0=none to 8=extreme.
Time frame: Baseline, 4 weeks
Population: The analysis included all randomized participants receiving at least 1 dose of the investigational product and with a baseline and at least 1 postbaseline WOMAC value.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| 80 mg LY2828360 | Change From Baseline to 4 Week Endpoint in Western Ontario and MacMaster (WOMAC) | WOMAC: Pain | -0.9 units on a scale | Standard Deviation 2.3 |
| 80 mg LY2828360 | Change From Baseline to 4 Week Endpoint in Western Ontario and MacMaster (WOMAC) | WOMAC: Stiffness | -0.5 units on a scale | Standard Deviation 1.4 |
| 80 mg LY2828360 | Change From Baseline to 4 Week Endpoint in Western Ontario and MacMaster (WOMAC) | WOMAC: Physical Function | -3.4 units on a scale | Standard Deviation 7.8 |
| Placebo | Change From Baseline to 4 Week Endpoint in Western Ontario and MacMaster (WOMAC) | WOMAC: Pain | -1.6 units on a scale | Standard Deviation 2.5 |
| Placebo | Change From Baseline to 4 Week Endpoint in Western Ontario and MacMaster (WOMAC) | WOMAC: Stiffness | -0.5 units on a scale | Standard Deviation 1.5 |
| Placebo | Change From Baseline to 4 Week Endpoint in Western Ontario and MacMaster (WOMAC) | WOMAC: Physical Function | -3.9 units on a scale | Standard Deviation 7.9 |
Secondary
Number of Participants With Treatment-Emergent Suicidal Ideation and Behaviors Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)
C-SSRS: scale capturing occurrence, severity, and frequency of suicide-related thoughts and behaviors. Number of participants with suicidal behaviors and ideations are provided. Suicidal behavior: a yes answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal ideation: a yes answer to any one of 5 suicidal ideation questions, which includes wish to be dead, and 4 different categories of active suicidal ideation.
Time frame: Baseline up to 15 weeks
Population: The C-SSRS analysis included all randomized participants.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 80 mg LY2828360 | Number of Participants With Treatment-Emergent Suicidal Ideation and Behaviors Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) | Treatment-Emergent Suicidal Ideation | 0 Participants |
| 80 mg LY2828360 | Number of Participants With Treatment-Emergent Suicidal Ideation and Behaviors Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) | Treatment-Emergent Suicidal Behaviors | 0 Participants |
| Placebo | Number of Participants With Treatment-Emergent Suicidal Ideation and Behaviors Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) | Treatment-Emergent Suicidal Ideation | 0 Participants |
| Placebo | Number of Participants With Treatment-Emergent Suicidal Ideation and Behaviors Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) | Treatment-Emergent Suicidal Behaviors | 0 Participants |
Secondary
Pharmacokinetics (PK) of LY2828360: Area Under the Concentration-Time Curve (AUC)
AUC from time zero to 8 hours (AUC0-8h) is reported for this outcome measure.
Time frame: Pre-last dose to 8 hours post-last dose (at end of each 4-week treatment period)
Population: The analysis included all randomized participants receiving at least 1 dose of LY2828360 with interpretable PK data.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| 80 mg LY2828360 | Pharmacokinetics (PK) of LY2828360: Area Under the Concentration-Time Curve (AUC) | 2803.9 nanogram*hour per milliliter (ng*h/mL) | Standard Deviation 775.8 |
Secondary
Pharmacokinetics (PK) of LY2828360: Maximal Concentration (Cmax)
Time frame: Pre-last dose to 8 hours post-last dose (at end of each 4-week treatment period)
Population: The analysis included all randomized participants receiving at least 1 dose of LY2828360 with interpretable PK data.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| 80 mg LY2828360 | Pharmacokinetics (PK) of LY2828360: Maximal Concentration (Cmax) | 464.4 nanogram per milliliter (ng/mL) | Standard Deviation 161 |